A Personalized Neoantigen Vaccine in Combination with Platinum-Based Chemotherapy Induces a T-Cell Response Coinciding with a Complete Response in Endometrial Carcinoma

Endometrial cancer (EC) is a common gynecological malignancy and the fourth most common malignancy in European and North American women. Amongst EC, the advanced serous, p53-mutated, and pMMR subtypes have the highest risk of relapse despite optimal standard of care therapy. At present, there is no...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Alexandre Harari, Apostolos Sarivalasis, Kaat de Jonge, Anne-Christine Thierry, Florian Huber, Caroline Boudousquie, Laetitia Rossier, Angela Orcurto, Martina Imbimbo, Petra Baumgaertner, Michal Bassani-Sternberg, Lana E. Kandalaft
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	endometrial cancer cancer vaccines immunotherapy neoantigens Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/54bbe941a68b4cdeb4848cf98f87ab84
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:54bbe941a68b4cdeb4848cf98f87ab84
record_format	dspace
spelling	oai:doaj.org-article:54bbe941a68b4cdeb4848cf98f87ab842021-11-25T17:04:10ZA Personalized Neoantigen Vaccine in Combination with Platinum-Based Chemotherapy Induces a T-Cell Response Coinciding with a Complete Response in Endometrial Carcinoma10.3390/cancers132258012072-6694https://doaj.org/article/54bbe941a68b4cdeb4848cf98f87ab842021-11-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/22/5801https://doaj.org/toc/2072-6694Endometrial cancer (EC) is a common gynecological malignancy and the fourth most common malignancy in European and North American women. Amongst EC, the advanced serous, p53-mutated, and pMMR subtypes have the highest risk of relapse despite optimal standard of care therapy. At present, there is no standard of care maintenance treatment to prevent relapse among these high-risk patients. Vaccines are a form of immunotherapy that can potentially increase the immunogenicity of pMMR, serous, and p53-mutated tumors to render them responsive to check point inhibitor-based immunotherapy. We demonstrate, for the first time, the feasibility of generating a personalized dendritic cell vaccine pulsed with peptide neoantigens in a patient with pMMR, p53-mutated, and serous endometrial adenocarcinoma (SEC). The personalized vaccine was administered in combination with systemic chemotherapy to treat an inoperable metastatic recurrence. This treatment association demonstrated the safety and immunogenicity of the personalized dendritic cell vaccine. Interestingly, a complete oncological response was obtained with respect to both radiological assessment and the tumor marker CA-125.Alexandre HarariApostolos SarivalasisKaat de JongeAnne-Christine ThierryFlorian HuberCaroline BoudousquieLaetitia RossierAngela OrcurtoMartina ImbimboPetra BaumgaertnerMichal Bassani-SternbergLana E. KandalaftMDPI AGarticleendometrial cancercancer vaccinesimmunotherapyneoantigensNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5801, p 5801 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	endometrial cancer cancer vaccines immunotherapy neoantigens Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	endometrial cancer cancer vaccines immunotherapy neoantigens Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Alexandre Harari Apostolos Sarivalasis Kaat de Jonge Anne-Christine Thierry Florian Huber Caroline Boudousquie Laetitia Rossier Angela Orcurto Martina Imbimbo Petra Baumgaertner Michal Bassani-Sternberg Lana E. Kandalaft A Personalized Neoantigen Vaccine in Combination with Platinum-Based Chemotherapy Induces a T-Cell Response Coinciding with a Complete Response in Endometrial Carcinoma
description	Endometrial cancer (EC) is a common gynecological malignancy and the fourth most common malignancy in European and North American women. Amongst EC, the advanced serous, p53-mutated, and pMMR subtypes have the highest risk of relapse despite optimal standard of care therapy. At present, there is no standard of care maintenance treatment to prevent relapse among these high-risk patients. Vaccines are a form of immunotherapy that can potentially increase the immunogenicity of pMMR, serous, and p53-mutated tumors to render them responsive to check point inhibitor-based immunotherapy. We demonstrate, for the first time, the feasibility of generating a personalized dendritic cell vaccine pulsed with peptide neoantigens in a patient with pMMR, p53-mutated, and serous endometrial adenocarcinoma (SEC). The personalized vaccine was administered in combination with systemic chemotherapy to treat an inoperable metastatic recurrence. This treatment association demonstrated the safety and immunogenicity of the personalized dendritic cell vaccine. Interestingly, a complete oncological response was obtained with respect to both radiological assessment and the tumor marker CA-125.
format	article
author	Alexandre Harari Apostolos Sarivalasis Kaat de Jonge Anne-Christine Thierry Florian Huber Caroline Boudousquie Laetitia Rossier Angela Orcurto Martina Imbimbo Petra Baumgaertner Michal Bassani-Sternberg Lana E. Kandalaft
author_facet	Alexandre Harari Apostolos Sarivalasis Kaat de Jonge Anne-Christine Thierry Florian Huber Caroline Boudousquie Laetitia Rossier Angela Orcurto Martina Imbimbo Petra Baumgaertner Michal Bassani-Sternberg Lana E. Kandalaft
author_sort	Alexandre Harari
title	A Personalized Neoantigen Vaccine in Combination with Platinum-Based Chemotherapy Induces a T-Cell Response Coinciding with a Complete Response in Endometrial Carcinoma
title_short	A Personalized Neoantigen Vaccine in Combination with Platinum-Based Chemotherapy Induces a T-Cell Response Coinciding with a Complete Response in Endometrial Carcinoma
title_full	A Personalized Neoantigen Vaccine in Combination with Platinum-Based Chemotherapy Induces a T-Cell Response Coinciding with a Complete Response in Endometrial Carcinoma
title_fullStr	A Personalized Neoantigen Vaccine in Combination with Platinum-Based Chemotherapy Induces a T-Cell Response Coinciding with a Complete Response in Endometrial Carcinoma
title_full_unstemmed	A Personalized Neoantigen Vaccine in Combination with Platinum-Based Chemotherapy Induces a T-Cell Response Coinciding with a Complete Response in Endometrial Carcinoma
title_sort	personalized neoantigen vaccine in combination with platinum-based chemotherapy induces a t-cell response coinciding with a complete response in endometrial carcinoma
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/54bbe941a68b4cdeb4848cf98f87ab84
work_keys_str_mv	AT alexandreharari apersonalizedneoantigenvaccineincombinationwithplatinumbasedchemotherapyinducesatcellresponsecoincidingwithacompleteresponseinendometrialcarcinoma AT apostolossarivalasis apersonalizedneoantigenvaccineincombinationwithplatinumbasedchemotherapyinducesatcellresponsecoincidingwithacompleteresponseinendometrialcarcinoma AT kaatdejonge apersonalizedneoantigenvaccineincombinationwithplatinumbasedchemotherapyinducesatcellresponsecoincidingwithacompleteresponseinendometrialcarcinoma AT annechristinethierry apersonalizedneoantigenvaccineincombinationwithplatinumbasedchemotherapyinducesatcellresponsecoincidingwithacompleteresponseinendometrialcarcinoma AT florianhuber apersonalizedneoantigenvaccineincombinationwithplatinumbasedchemotherapyinducesatcellresponsecoincidingwithacompleteresponseinendometrialcarcinoma AT carolineboudousquie apersonalizedneoantigenvaccineincombinationwithplatinumbasedchemotherapyinducesatcellresponsecoincidingwithacompleteresponseinendometrialcarcinoma AT laetitiarossier apersonalizedneoantigenvaccineincombinationwithplatinumbasedchemotherapyinducesatcellresponsecoincidingwithacompleteresponseinendometrialcarcinoma AT angelaorcurto apersonalizedneoantigenvaccineincombinationwithplatinumbasedchemotherapyinducesatcellresponsecoincidingwithacompleteresponseinendometrialcarcinoma AT martinaimbimbo apersonalizedneoantigenvaccineincombinationwithplatinumbasedchemotherapyinducesatcellresponsecoincidingwithacompleteresponseinendometrialcarcinoma AT petrabaumgaertner apersonalizedneoantigenvaccineincombinationwithplatinumbasedchemotherapyinducesatcellresponsecoincidingwithacompleteresponseinendometrialcarcinoma AT michalbassanisternberg apersonalizedneoantigenvaccineincombinationwithplatinumbasedchemotherapyinducesatcellresponsecoincidingwithacompleteresponseinendometrialcarcinoma AT lanaekandalaft apersonalizedneoantigenvaccineincombinationwithplatinumbasedchemotherapyinducesatcellresponsecoincidingwithacompleteresponseinendometrialcarcinoma AT alexandreharari personalizedneoantigenvaccineincombinationwithplatinumbasedchemotherapyinducesatcellresponsecoincidingwithacompleteresponseinendometrialcarcinoma AT apostolossarivalasis personalizedneoantigenvaccineincombinationwithplatinumbasedchemotherapyinducesatcellresponsecoincidingwithacompleteresponseinendometrialcarcinoma AT kaatdejonge personalizedneoantigenvaccineincombinationwithplatinumbasedchemotherapyinducesatcellresponsecoincidingwithacompleteresponseinendometrialcarcinoma AT annechristinethierry personalizedneoantigenvaccineincombinationwithplatinumbasedchemotherapyinducesatcellresponsecoincidingwithacompleteresponseinendometrialcarcinoma AT florianhuber personalizedneoantigenvaccineincombinationwithplatinumbasedchemotherapyinducesatcellresponsecoincidingwithacompleteresponseinendometrialcarcinoma AT carolineboudousquie personalizedneoantigenvaccineincombinationwithplatinumbasedchemotherapyinducesatcellresponsecoincidingwithacompleteresponseinendometrialcarcinoma AT laetitiarossier personalizedneoantigenvaccineincombinationwithplatinumbasedchemotherapyinducesatcellresponsecoincidingwithacompleteresponseinendometrialcarcinoma AT angelaorcurto personalizedneoantigenvaccineincombinationwithplatinumbasedchemotherapyinducesatcellresponsecoincidingwithacompleteresponseinendometrialcarcinoma AT martinaimbimbo personalizedneoantigenvaccineincombinationwithplatinumbasedchemotherapyinducesatcellresponsecoincidingwithacompleteresponseinendometrialcarcinoma AT petrabaumgaertner personalizedneoantigenvaccineincombinationwithplatinumbasedchemotherapyinducesatcellresponsecoincidingwithacompleteresponseinendometrialcarcinoma AT michalbassanisternberg personalizedneoantigenvaccineincombinationwithplatinumbasedchemotherapyinducesatcellresponsecoincidingwithacompleteresponseinendometrialcarcinoma AT lanaekandalaft personalizedneoantigenvaccineincombinationwithplatinumbasedchemotherapyinducesatcellresponsecoincidingwithacompleteresponseinendometrialcarcinoma
_version_	1718412775561101312

A Personalized Neoantigen Vaccine in Combination with Platinum-Based Chemotherapy Induces a T-Cell Response Coinciding with a Complete Response in Endometrial Carcinoma

Ejemplares similares